Targeted Oncology - Immunotherapy, Biomarkers, and
•
25th July 2020
Targeting KRAS-Mutant Tumors With Indirect Targeting of Related Pathways Yields Hope in Solid Tumors | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Targeting component of signal transduction pathways associated with KRAS may be the long-awaited solution for management of certain cancers harboring KRAS mutations, once considered an undruggable target, according to promising results from early-stage clinical trials. However, the efficacy of each combination therapy will likely depend on the tumor lineage, Gordon Mills, MD, PhD, told Targeted Therapies in Oncology in an interview.KRAS mutations are common in multiple types of cancer, including...